
==== Front
Drug Healthc Patient Saf
Drug Healthc Patient Saf
dhps
Drug, Healthcare and Patient Safety
1179-1365
Dove

487045
10.2147/DHPS.S487045
Letter
Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone [Letter]
Rahman
Rahman
Rahman Nuril Endi 1
1 Social Welfare Study Program, Muhammadiyah Madiun University, Madiun City, Indonesia
Correspondence: Nuril Endi Rahman, Email ner847@ummad.ac.id
04 9 2024
2024
16 103104
15 7 2024
01 9 2024
© 2024 Rahman.
2024
Rahman.
https://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
==== Body
pmcDear editor

We are very interested in the research titled “Adverse Events Following Immunization With Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone” which explores the effectiveness and challenges of vaccinating children affected by the polio outbreak in Sierra Leone.1 This paper briefly and clearly describes the emergence of the cVDPV2 outbreak in Sierra Leone, which affected children in the country. Besides that, this study uses a mixed-method approach and a dense population to describe the effectiveness of vaccine implementation and the extent to which vaccine implementers achieve success and overcome various obstacles. However, more work is needed to add a medical perspective on AEFI, and provide hypotheses related to adverse events. There is a need for focus group discussion to understand the participants who are vaccinators and to get a more specific sketch and capture a more complete perception of the client.2 In addition, an explanation or narrative about of AEFI is needed based on findings in the field, and to reinforce the finding that vaccination has no causal relationship to the occurrence of AEFI. Thus, the public does not need to be afraid to receive vaccines, because it is clear that the cause of adverse symptoms is not caused by vaccination.

Disclosure

The author reports no conflicts of interest in this communication.
==== Refs
References

1. Thomas F, Abiri OT, Kallon JM, et al. Adverse events following immunization with novel oral polio vaccine type 2, and the experience and challenges of reporting in Sierra Leone. Drug Healthc Pat Saf. 2024;Volume 16 :61–73. doi:10.2147/DHPS.S466039
2. Aslani P, Hamrosi K, Tong V, et al. Consumer opinions on adverse events associated with medicines and vaccines. Patient Prefer Adher. 2018;Volume 12 :1383–1392. doi:10.2147/PPA.S167396
